AstraZeneca to co-promote J&J prostate cancer drug in Japan

[riky]

AstraZeneca to co-promote J&J prostate cancer drug in Japan

LONDON (Reuters) - AstraZeneca has signed a deal to co-promote Johnson & Johnson's novel prostate cancer medicine in Japan, giving the British company a new drug revenue stream and bolstering its Japanese presence. Financial terms of the agreement, announced by AstraZeneca on Friday, were not disclosed. The drug, abiraterone, was submitted for regulatory approval in Japan in July 2013. It is already on the market in the United States and Europe, where it is sold under the brand name Zytiga. ...

Source: You are not allowed to view links. Register or Login